This is from the AASLD (American Association for the Study of Liver Disease) treatment guidelines for genotype 3 treatment naïve:
Genotype 3 Treatment-Naïve Patients Without Cirrhosis - Recommended
Recommended regimens are listed in groups by level of evidence, then alphabetically.
Daily daclatasvir (60 mg*) plus sofosbuvir (400 mg) for 12 weeks is a Recommended regimen for treatment-naïve patients with HCV genotype 3 infection who do not have cirrhosis.
Rating: Class I, Level A
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) for 12 weeks is a Recommended regimen for treatment-naïve patients with HCV genotype 3 infection who do not have cirrhosis.
Rating: Class I, Level A
* The dose of daclatasvir may need to increase or decrease when used concomitantly with cytochrome P450 3A/4 inducers and inhibitors, respectively. Please refer to the prescribing information and the section on HIV/HCV coinfection for patients on antiretoviral therapy.
http://www.hcvguidelines.org/full-report/initial-treatment-box-summary-recommendations-patients-who-are-initiating-therapy-hcv
Ledipisvir Sovaldi is Harvoni and you are correct it is not a recommended treatment per the AASLD as the two listed above are more effective.
The first drug listed as daclatasvir (60 mg*) plus sofosbuvir is called by the trade name Daklinza.
The second drug above sofosbuvir (400 mg)/velpatasvir (100 mg) is called Epclusa.
Is your doctor experienced in treating hep c and is current with the state of new treatments?
Ask him if he is familiar with Epclusa and Daklinza
Here is some additional information from the University of Washington in Seattle
http://www.hepatitisc.uw.edu/go/treatment-infection/treatment-genotype-3/core-concept/all